Companies › MAXVAX Biotechnology Limited Liability Company
4 active drug programs in 12 registered trials: 5 Phase 1, 4 Phase 2, 3 Phase 3; Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose Recombinant RSV vaccine | RSV | Phase 3 | Respiratory Syncytial Virus (RSV); Respiratory Syncytial Virus Infections | Feb 2027 |
| Varicella Zoster Virus Envelope Glycoprotein E Envelope glycoprotein E vaccine antigen | VZGP5, VZV | Phase 3 | Herpes Zoster | Nov 2027 |
| Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 Recombinant varicella zoster virus glycoprotein E vaccine with low dose MA105 adjuvant | VZV, VZVA | Phase 2 | Herpes Zoster | – |
| Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose) Recombinant rotavirus subunit vaccine with P types; adjuvanted with aluminum hydroxide | ROTV | Phase 2 | Rotavirus Infections | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05621655 | Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose) | Phase 2 | Rotavirus Infections | Infectious disease | Apr 2023 |
| NCT05621655 | Recombinant Trivalent Subunit Rotavirus Vaccine (Mid dose) | Phase 2 | Rotavirus Infections | Infectious disease | Apr 2023 |
| NCT05636436 | Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 | Phase 1 | Herpes Zoster | Infectious disease | May 2025 |
| NCT05636436 | Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 | Phase 1 | Herpes Zoster | Infectious disease | May 2025 |
| NCT05856084 | Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 | Phase 2 | Herpes Zoster | Infectious disease | Sep 2025 |
| NCT05856084 | Recombinant Herpes Zoster Vaccine (CHO cells) with low dose MA105 | Phase 2 | Herpes Zoster | Infectious disease | Sep 2025 |
| NCT06642558 | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Feb 2027 |
| NCT06642558 | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose | Phase 1 | Respiratory Syncytial Virus (RSV) | Infectious disease | Feb 2027 |
| NCT07582796 | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose | Phase 1 | Respiratory Syncytial Virus Infections | Infectious disease | Sep 2027 |
| NCT06447779 | Varicella Zoster Virus Envelope Glycoprotein E | Phase 3 | Herpes Zoster | Infectious disease | Nov 2027 |
| NCT07293065 | Varicella Zoster Virus Envelope Glycoprotein E | Phase 3 | Herpes Zoster | Infectious disease | Dec 2027 |
| NCT07272434 | Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells), low dose | Phase 3 | Respiratory Syncytial Virus (RSV) | Infectious disease | Dec 2028 |
Sanofi ModernaTX Green Cross Guangzhou Patronus Biotech AstraZeneca Enanta Pharmaceuticals Shenzhen Shenxin Biotechnology GSK
Shenzhen Shenxin Biotechnology Aimei Vacin BioPharm (Zhejiang) Biothervax Xiamen Innovax Biotech OsteoRemedies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.